These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27317801)

  • 1. Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.
    Lai Y; Mandlekar S; Shen H; Holenarsipur VK; Langish R; Rajanna P; Murugesan S; Gaud N; Selvam S; Date O; Cheng Y; Shipkova P; Dai J; Humphreys WG; Marathe P
    J Pharmacol Exp Ther; 2016 Sep; 358(3):397-404. PubMed ID: 27317801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects.
    Shen H; Chen W; Drexler DM; Mandlekar S; Holenarsipur VK; Shields EE; Langish R; Sidik K; Gan J; Humphreys WG; Marathe P; Lai Y
    Drug Metab Dispos; 2017 Aug; 45(8):908-919. PubMed ID: 28576766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species.
    Shen H; Dai J; Liu T; Cheng Y; Chen W; Freeden C; Zhang Y; Humphreys WG; Marathe P; Lai Y
    J Pharmacol Exp Ther; 2016 May; 357(2):382-93. PubMed ID: 26907622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and urinary CP I and CP III concentrations in chimeric mice with human hepatocytes after rifampicin administration.
    Shishido Y; Yoshida T; Oshida K; Uchida M
    Pharmacol Res Perspect; 2024 Oct; 12(5):e70017. PubMed ID: 39312270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression.
    Zhang Y; Chen C; Chen SJ; Chen XQ; Shuster DJ; Puszczalo PD; Fancher RM; Yang Z; Sinz M; Shen H
    J Pharmacol Exp Ther; 2020 Oct; 375(1):139-151. PubMed ID: 32719071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
    Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
    Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III.
    Bednarczyk D; Boiselle C
    Xenobiotica; 2016; 46(5):457-66. PubMed ID: 26383540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study.
    Kalluri HV; Kikuchi R; Coppola S; Schmidt J; Mohamed MF; Bow DAJ; Salem AH
    Clin Transl Sci; 2021 Jan; 14(1):373-381. PubMed ID: 33048456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UHPLC-MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions.
    Kandoussi H; Zeng J; Shah K; Paterson P; Santockyte R; Kadiyala P; Shen H; Shipkova P; Langish R; Burrrell R; Easter J; Mariannino T; Marathe P; Lai Y; Zhang Y; Pillutla R
    Bioanalysis; 2018 May; 10(9):633-644. PubMed ID: 29749254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A highly selective and sensitive LC-MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting peptide biomarkers.
    Ramanathan R; King-Ahmad AJ; Holliman CL; Rodrigues AD
    Bioanalysis; 2017 Nov; 9(22):1787-1806. PubMed ID: 28978230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coproporphyrin-I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug-Drug Interactions: Cedirogant Case Study.
    Kikuchi R; Qian Y; Badawi M; Savaryn JP; Gannu S; Eldred A; Hao S; Salem AH; Liu W; Klein CE; Mohamed MF
    Clin Pharmacol Ther; 2024 Nov; 116(5):1334-1342. PubMed ID: 39102854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions.
    Njumbe Ediage E; Dillen L; Vroman A; Diels L; Kunze A; Snoeys J; Verhaeghe T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():80-89. PubMed ID: 29241088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fully automated and validated human plasma LC-MS/MS assay for endogenous OATP biomarkers coproporphyrin-I and coproporphyrin-III.
    King-Ahmad A; Clemens S; Ramanathan R; Zhang Y; Raha N; Zhang Y; Holliman C; Rodrigues AD; Li F
    Bioanalysis; 2018 May; 10(9):691-701. PubMed ID: 29747517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo.
    Niu C; Wang Y; Zhao X; Tep S; Murakami E; Subramanian R; Smith B; Lai Y
    Drug Metab Dispos; 2019 Dec; 47(12):1433-1442. PubMed ID: 31582395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition-Progress from 2016 to 2023.
    Lai Y
    Drug Metab Dispos; 2023 Aug; 51(8):950-961. PubMed ID: 37407093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.
    Yee SW; Giacomini MM; Shen H; Humphreys WG; Horng H; Brian W; Lai Y; Kroetz DL; Giacomini KM
    Clin Transl Sci; 2019 Jul; 12(4):388-399. PubMed ID: 30982223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions.
    Mochizuki T; Zamek-Gliszczynski MJ; Yoshida K; Mao J; Taskar K; Hirabayashi H; Chu X; Lai Y; Takashima T; Rockich K; Yamaura Y; Fujiwara K; Mizuno T; Maeda K; Furihata K; Sugiyama Y; Kusuhara H
    Clin Pharmacol Ther; 2022 Jun; 111(6):1315-1323. PubMed ID: 35292967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
    Zhang Y; Holenarsipur VK; Kandoussi H; Zeng J; Mariappan TT; Sinz M; Shen H
    Drug Metab Dispos; 2020 Oct; 48(10):841-848. PubMed ID: 32723847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys.
    Cheng Y; Liang X; Hao J; Niu C; Lai Y
    Clin Transl Sci; 2021 Sep; 14(5):1924-1934. PubMed ID: 34058067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
    Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
    Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.